FILINGS
| GSK 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2024-08-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-08-20 | 6-K | B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION | View Document |
| 2024-08-16 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-08-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-08-06 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-08-02 | 6-K | FDA EXPANDS JEMPERLI APPROVAL | View Document |
| 2024-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-07-31 | 6-K | 2ND QUARTER RESULTS | View Document |
| 2024-07-29 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-07-29 | 6-K | CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK | View Document |
| 2024-07-19 | 6-K | BLENREP EMA FILING ACCEPTANCE | View Document |
| 2024-07-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-16 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-07-03 | 6-K | GSK AND CUREVAC COLLABORATION RESTRUCTURED | View Document |
| 2024-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-06-28 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-24 | 6-K | EMA VALIDATES JEMPERLI MARKETING AUTHORISATION | View Document |
| 2024-06-24 | 6-K | OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS | View Document |
| 2024-06-21 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2024-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2024-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-06-11 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-10 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-06-10 | 6-K | FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK | View Document |
| 2024-06-03 | 25-NSE | View Document | |
| 2024-06-03 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-06-03 | 6-K | UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE | View Document |
| 2024-06-03 | 6-K | ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS | View Document |
| 2024-06-03 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-05-31 | SD | SPECIALIZED DISCLOSURE REPORT | View Document |
| 2024-05-24 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-05-21 | 6-K | POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB | View Document |
| 2024-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-05-17 | 6-K | CURRENT REPORT | View Document |
| 2024-05-17 | 6-K | GSK COMPLETES SALE OF SHARES IN HALEON PLC | View Document |
| 2024-05-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-05-13 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2024-05-08 | 6-K | RESULT OF AGM | View Document |
| 2024-05-08 | 6-K | BOARD COMMITTEE CHANGE | View Document |
| 2024-05-03 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-05-01 | 6-K | 1ST QUARTER RESULTS | View Document |
| 2024-05-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-04-24 | 6-K | US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI | View Document |
| 2024-04-19 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-04-17 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-04-17 | 6-K | RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX | View Document |
| 2024-04-17 | 6-K | GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS | View Document |
| 2024-04-16 | 6-K | AMENDMENT - DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-04-16 | 6-K | FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE | View Document |
| 2024-04-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-04-04 | 6-K/A | REPLACEMENT - TOTAL VOTING RIGHTS | View Document |
| 2024-04-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-03-28 | SC 13D/A | AMENDMENT TO FORM SC 13D | View Document |
| 2024-03-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-03-25 | F-3ASR | F-3ASR | View Document |
| 2024-03-25 | 6-K | NOTICE OF AGM | View Document |
| 2024-03-22 | 6-K | TRANSFER OF TREASURY SHARES | View Document |
| 2024-03-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-03-18 | 6-K | NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER | View Document |
| 2024-03-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-03-08 | 6-K | BOARD COMMITTEE CHANGE | View Document |
| 2024-03-07 | 6-K | GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS | View Document |
| 2024-03-06 | 6-K | VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED | View Document |
| 2024-03-05 | 6-K | GSK ANNUAL REPORT 2023 ON FORM 20 F | View Document |
| 2024-03-05 | IRANNOTICE | IRANNOTICE | View Document |
| 2024-03-05 | 20-F | 20-F | View Document |
| 2024-03-05 | 6-K | NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING | View Document |
| 2024-03-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-03-01 | 6-K | GSK PUBLISHES ANNUAL REPORT 2023 | View Document |
| 2024-02-29 | 6-K | DIRECTORATE CHANGE | View Document |
| 2024-02-29 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-02-26 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-26 | 6-K | GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS | View Document |
| 2024-02-22 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-21 | 6-K | VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED | View Document |
| 2024-02-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-15 | 6-K | GSK COMPLETES ACQUISITION OF AIOLOS BIO | View Document |
| 2024-02-13 | SC 13G/A | SC 13G/A | View Document |
| 2024-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-12 | 6-K | US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN | View Document |
| 2024-02-09 | SC 13D/A | AMENDMENT TO SC 13D | View Document |
| 2024-02-06 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2024-02-06 | SC 13G/A | AMENDMENT TO FORM SC 13G | View Document |
| 2024-02-06 | 6-K | FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK | View Document |
| 2024-02-06 | 6-K | SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED | View Document |
| 2024-02-06 | 6-K | GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA | View Document |
| 2024-02-01 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2024-02-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2024-02-01 | 6-K | STATEMENT: ZANTAC (RANITIDINE) LITIGATION | View Document |
| 2024-01-31 | 6-K | FINAL RESULTS | View Document |
| 2024-01-30 | 4 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
